Human / Cynomolgus VEGF / VEGFA / VEGF165 Protein 11066-HNAH from Sino Biological, Inc.

Product Specs
ItemHuman / Cynomolgus VEGF / VEGFA / VEGF165 Protein
CompanySino Biological, Inc.
Price $598.00Supplier Page View Company Product Page
Catalog Number11066-HNAH
Conjugate/TagUnconjugated
Purity≥ 95 % as determined by SDS-PAGE. ≥ 95 % as determined by SEC-HPLC. ≥ 95 % as determined by SEC-MALS(Routinely tested)
TypeRecombinant protein
Molecular WeightThe recombinant human / cynomolgus VEGF165 consists of 165 amino acids and predicts a molecular mass of 19.2 KDa. It migrates as an approximately 22 kDa and 24 kDa band in SDS-PAGE under reducing conditions. The molecular weight of this protein is around 44.9 kDa verified by SEC-MALS(Routinely tested)
SpeciesHuman, Cynomolgus
Molecule NameVEGFA
Source/Expression SystemHEK293 Cells
Activity1.iPSC-derived human vascular organoids (Day 7) were cultured with FGF2 (Cat#10014-HNAE), VEGFA (Cat# 11066-HNAH), EGF (Cat#10605-HNAE). Red arrows represent vascular organoids. Image taken at 10x magnification.(Routinely tested) 2. Measured in a cell proliferation assay using human umbilical vein endothelial cells (HUVEC). The ED50 for this effect is typically 2-10 ng/mL. 3. Anti-VEGF (Research Grade Bevaciz*mab Biosimilar) captured on Protein A chip can bind Recombinant Human, Cynomolgus VEGF165 Protein (Cat. No. 11066-HNAH) with an affinity constant of 14.9 pM as determined in an SPR assay (Biacore 8K) (Routinely tested). 4.Loaded Biotinylated Recombinant Human VEGFR1/FLT1 Protein, His & AVI Tag (Cat. No. 10136-H49H-B) on SA Biosensor, can bind Recombinant VEGF165 Protein, Human, Cynomolgus (Cat. No. 11066-HNAH) with an affinity constant of 0.506 nM as determined in BLI assay (Sartorius Octet RED384) (Routinely tested)
FormatLyophilized from sterile 20mM Tris, 150mM NaCl, pH 8.0
Size100 µg

Add to Compare List

Sino Biological, Inc.

37 Industrial Blvd

Suite B

Paoli, PA 19301

United States

Phone: 215-583-7898
Fax: 267-657-0217

Email: marketing@sinobiological.com

Company Profile

Website: sinobiological.com

(1) TAL1 is indispensable in ETV2-primed human endothelial cell fate determinationSci AdvAugust 14, 2026Yun Zhao, Mengze Sun, Zixuan Hong, Jingkun Yi, Donglin Yu, Xiaojing Ma, Liangliang Tian, Yi Hong, Lijun Sun, Xiaoxia Li, et al.LaSR supplemented with FGF2 (50 ng/ml; SinoBiological, 10014-HNAE), VEGFA (50 ng/ml; SinoBiological, 11066-HNAH), EGF (10 ng/ml; SinoBiological, 10605-HNAE), and 10 μM SB431542 (Topscience, T1726) for 72 hours. Medium

(2) G6PD deficiency is implicated in Circle of Willis variants in stroke patients and impairs brain vasculature in zebrafishJournal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and MetabolismMarch 1, 2026Cai Y, Li J, Chen Y, Ou Z, Wei J, Long X, Xiong Z, Yang M, He Y, Yan H, et al.

(3) IMM2510, a novel anti-PD-L1/VEGF bispecific antibody for cancer immunotherapyAntibody TherapeuticsJanuary 15, 2026Dianze Chen, Zhuli Wu, Xiwen Zhao, Rupal S Bhatt, Yanan Yang, Wenqi Zhu, Huang Tang, Kaili Wang, Chunli Guo, Dandan Liu, et al.and antibodies The recombinant proteins used included: Human VEGF-A (VEGF165) (Sino Biological, Cat#11066-HNAH), Human VEGF-B (Acro Biosystems, Cat#VE6-H5225), Human VEGF-C (Sino Biological, Cat# 10542-H08H), Human

(4) SPARK-seq: A high-throughput platform for aptamer discovery and kinetic profilingScience (New York, N.Y.)January 1, 2026Luo G, Song J, Fu Y, Jiang Y, Gao Y, Zhong Z, Li L, Wei Y, Jia HR, Guo L, et al.

(5) Gamma-synuclein drives bevacizumab resistance in colorectal cancer via VEGFR2 activation and angiogenesisDrug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapyJanuary 1, 2026Liu C, Meng L, Wang L, Dong B, Qu L, Zhao C, Shou C.

(6) Anti-angiogenesis enhances the tumor immunotherapeutical effect of recombinant CD80 fusion proteinInternational journal of biological macromoleculesSeptember 1, 2025Wang S, Huang L, Zhang X, Fan J, Zou J, Hong W, Tuerdi A, Zhu YZ, Hu P, Ye L.

(7) Galectin-3-integrin α5β1 phase separation disrupted by advanced glycation end-products impairs diabetic wound healing in rodentsNature communicationsAugust 7, 2025Zhang Z, Zhao Z, Huang X, Zhou L, Jiang X, Wu H, Liu C, Huang K, Wen J, Liu Y, et al.

(8) Generation of iPSC-derived human venous endothelial cells for the modeling of vascular malformations and drug discoveryCell stem cellFebruary 6, 2025Pan Z, Yao Q, Kong W, Ma X, Tian L, Zhao Y, Zhu S, Chen S, Sun M, Liu J, et al.

(9) Enhancing In Vivo Electroporation Efficiency through Hyaluronidase: Insights into Plasmid Distribution and Optimization StrategiesPharmaceuticsApril 17, 2024Maji D, Miguela V, Cameron AD, Campbell DA, Sasset L, Yao X, Thompson AT, Sussman C, Yang D, Miller R, et al.Scientific). For the EBV321 ELISA, human/cynomolgus VEGF/VEGFA/VEGF165-20 protein (Sino Biological #11066-HNAH, Beijing, China) antigen at a concentration of 8 µg/mL was used; for the 1219 ELISA, SARS-CoV-2 (2019-nCoV) spike RBD-His recombinant protein

(10) Rapid conversion of porcine pluripotent stem cells into macrophages with chemically defined conditionsThe Journal of biological chemistryJanuary 1, 2024Wu X, Ni Y, Li W, Yang B, Yang X, Zhu Z, Zhang J, Wu X, Shen Q, Liao Z, et al.refreshed with the differentiation medium supplemented with 50 ng/ml VEGFA (Sino Biological, cat. no.11066-HNAH), 50 ng/ml bFGF (Sino Biological, cat. no. 10014-HNAE), 50 ng/ml SCF (Novoprotein, cat. no. C034), and

(11) Integrative epigenomic and transcriptomic analysis reveals the requirement of JUNB for hematopoietic fate inductionNature communicationsJune 6, 2022Chen X, Wang P, Qiu H, Zhu Y, Zhang X, Zhang Y, Duan F, Ding S, Guo J, Huang Y, et al.onto Matrigel-coated dishes at a density of 4 × 104 cells/cm2 in basal medium with 50 ng/ml VEGF165 (11066-HNAH, Sino Biological) and 10 ng ng/ml FGF2 (10014-HNAE, Sino Biological) for 48 h. The medium was replaced

(12) Enhanced anti-angiogenetic effect of transferrin receptor-mediated delivery of VEGF-trap in a glioblastoma mouse modelmAbsJanuary 1, 2022Zhao P, Anami Y, Gao P, Fan X, Li L, Tsuchikama K, Zhang N, An Z.density of 1 × 104 per well in assay medium (F12K+ 2% FBS) with 50 ng/μL human VEGFA (Sino Biological 11066-HNAH) but without the growth factor supplement. To start the assay, the medium was replaced with assay medium

(13) Modular fluorescent nanoparticle DNA probes for detection of peptides and proteinsScientific reportsOctober 7, 2021Stawicki CM, Rinker TE, Burns M, Tonapi SS, Galimidi RP, Anumala D, Robinson JK, Klein JS, Mallick P.Multipep RSi synthesizer. Recombinant Her2-his (Sino Biological, 1004H08H) and VEGF (Sino Biological, 11066-HNAH) were resuspended according to the manufacturer’s protocol, aliquoted, and stored at − 80 °C. Myoglobin

(14) A Novel Bispecific Antibody Targeting PD-L1 and VEGF With Combined Anti-Tumor ActivitiesFrontiers in immunologyJanuary 1, 2021Cui X, Jia H, Xin H, Zhang L, Chen S, Xia S, Li X, Xu W, Chen X, Feng Y, et al.measure the binding affinity to PD-L1, the system was firstly injected with 10nM human VEGF165 protein (11066-HNAH, Sino Biological Inc.) to saturate VEGF binding by HB0025, followed by the addition of 50 nM human PD-L1

(15) An efficient protein production system via gene amplification on a human artificial chromosome and the chromosome transfer to CHO cellsScientific reportsNovember 18, 2019Ohira T, Miyauchi K, Uno N, Shimizu N, Kazuki Y, Oshimura M, Kugoh H.NV1 was previously reported as a CHO genome reference for qPCR29. ELISA VEGF 165 antigen protein (11066-HNAH, Sino Biological, Beijing, China) was diluted with PBS to 50 ng/well, added to a 96-well plate, and

(16) Endothelial CDS2 deficiency causes VEGFA-mediated vascular regression and tumor inhibitionCell researchNovember 1, 2019Zhao W, Cao L, Ying H, Zhang W, Li D, Zhu X, Xue W, Wu S, Cao M, Fu C, et al.Transcription Kit (Ambion). For protein delivery into circulation, 1–2 nl VEGF-A (Sino Biological, 11066-HNAH-5; 250 μg ml−1) or FGF2 (Novoprotein, C044; 200 μg ml−1) dissolved in water was injected into the common

(17) Efficient Production of a Bioactive Bevacizumab Monoclonal Antibody Using the 2A Self-cleavage Peptide in Transgenic Rice CallusFrontiers in plant scienceJanuary 1, 2016Chen L, Yang X, Luo D, Yu W.rice-derived Bevacizumab to its antigen was assessed by using a VEGF antigen binding ELISA. The antigen hVEGF (11066-HNAH, Sino Biological Inc, Beijing, China) solution in 1× PBS (50 µL, 0.5 µg/mL) was coated onto 96-well

Be the First to Write a Review!

Human / Cynomolgus VEGF / VEGFA / VEGF165 Protein

Human / Cynomolgus VEGF / VEGFA / VEGF165 Protein from Sino Biological, Inc.

Description

Sino Biological, Inc.

Citations (17)

Reviews

Human / Cynomolgus VEGF / VEGFA / VEGF165 Protein from Sino Biological, Inc.

About Biocompare

Advertise with Us

Specialized Search Tools

Site Map